pipette
ESEspañol

Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer

Ying Fan, Yunjiang Liu, Yongsheng Wang, Quchang Ouyang, Qingyuan Zhang, Jiuwei Cui, Jingruo Li, Qiang Ding, Xinhong Wu, Xiaojia Wang, Zhongsheng Tong, Yinduo Zeng, Wenhui Wang, Min Yan, Yili Wang, Xiaoyu Liu, Kai Li, Zhengkui Sun, Chunxiu Yuan, Ting Wang, Weimin Xie, Jing Yao, Shoubing Zhou, Jialin Hou, Zhong Ouyang, 李怡婧, Sisi Cui, Xia Zhang, Xiaoyu Zhu, Binghe Xu

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Conclusions and Relevance Trastuzumab rezetecan provided significant progression-free survival benefit over physician’s choice of chemotherapy in patients with ERBB2-low advanced breast cancer, with benefit observed across all key subgroups.

Appeared: Sunday, October 25. JAMA. Peer-reviewed journal.

DOI: 10.1001/jama.2026.21372